In­novent Bi­o­log­ic­s' ADC can­di­date has passed a Phase 3 tri­al in ad­vanced stom­ach can­cer and is un­der pri­or­i­ty re­view in Chi­na, but de­tails of the...

👥 Ful­crum Ther­a­peu­tics re­duced to a shell: The biotech is let­ting go 48 of its 57 full-time em­ploy­ees, ac­cord­ing to an SEC fil­ing. The...

Ot­su­ka Phar­ma­ceu­ti­cal re­port­ed new ev­i­dence on Thurs­day that it thinks will help sup­port a full ap­proval for its mon­o­clon­al an­ti­body Voyx­act in a chron­ic au­toim­mune...

Act­ing FDA Com­mis­sion­er Kyle Dia­man­tas is­n't in­ter­est­ed in keep­ing the job and the search for a per­ma­nent re­place­ment is pro­gress­ing, ac­cord­ing to a source fa­mil­iar...

Uli Stilz has been trot­ting the globe this year to talk about the fu­ture of biotech and bridge an in­creas­ing­ly in­ter­na­tion­al in­dus­try. He was in...